At ILEX, we continue to research and acquire compounds with unique mechanisms of action, targeting novel receptors. We are focused on building a portfolio of oncology compounds that are different than those already available to patients and that provide new hope with effective and safe treatments for cancer.
The ILEX history of drug development remains the core competency of the company and is now focused on ILEX's own pipeline. In addition to its strong scientific and clinical staff, ILEX has a knowledgeable management team with extensive pharmaceutical industry experience.
ILEX is building a product-driven biopharmaceutical company focused primarily in oncology. ILEX has a marketed product, CAMPATH® (alemtuzumab) in the United States and MABCAMPATH® in the European Union, and is advancing an innovative and diversified pipeline of compounds.
